The present fee-for-service payment model that dominates healthcare doesn't begin to meet what needs to be done to properly treat people with open wounds and diabetes. That was the primary complaint heard at an experts panel that the life sciences trade group LifeScience Alley held in downtown Minneapolis on Wednesday.
Eden Prairie-based Celleration has raised $8 million in Series E stock toward more sales and marketing resources for its mist therapy wound healing product. CEO Mark Wagner, who joined the company in 2009, said by phone that Celleration attracted a new Minneapolis-based investor Sightline Partners for this latest round, despite a dismal venture capital climate. Past investors such as Affinity Capital, Venture Investors, Triathlon Medical Ventures, Baird Venture Partners and New Science Ventures also contributed, leaving $112,996 in shares for the total goal as yet unsold. "I'm pleased that our investors have expressed their confidence in our team as well as the opportunity for mist therapy," Wagner said. "We had a very good 2010, and we're looking to drive our revenue in 2011."
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
If patience is a virtue, then Minnesota venture capitalists have become downright saintly. Faced with a weak economy that has stifled initial public offerings and mergers and acquisitions, local investors are still looking for exits well after the funds have closed. Throw in tougher regulatory scrutiny for medical devices and drugs and an exit can […]
Aside from sharing the same first letter, “mojo” and “Minnesota” are words that don’t seem to carry a lot in common, though that may soon change. The state is home to 19 Fortune 500 companies, a world-class hospital and research center in Rochester and SPAM–what else do you need? But the land of 10,000 lakes […]